Essential Fatty Acids in Antiin ammatory Therapy for Dry Eye Disease

KENNETH A. BECKMAN, MD Developing novel pharmaceuticals and improving upon available agents have been of longstanding interest in ophthalmology. An exciting current trend is taking established drugs and delivering them to the eye by novel mechanisms in order to reduce the burden of drops on patients and improve pharmacodynamics, safety, and outcomes. Newly approved and pipeline agents are forwarding the universal trend toward dropless in ammation control post-cataract surgery.

[1]  T. Ajith,et al.  Omega‐3 fatty acids in coronary heart disease: Recent updates and future perspectives , 2018, Clinical and experimental pharmacology & physiology.

[2]  D. Musch,et al.  Dry Eye Syndrome Preferred Practice Pattern®. , 2019, Ophthalmology.

[3]  T. Ajith.  A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer's Disease. , 2019, Current clinical pharmacology.

[4]  E. Holland,et al.  Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery: A Randomized, Placebo-Controlled, Phase III Trial. , 2018, Ophthalmology.

[5]  C. Schacky.  Bioavailability of Marine n-3 Fatty Acid Formulations , 2018 .

[6]  Roni M. Shtein,et al.  n‐3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease , 2018, The New England journal of medicine.

[7]  S. Kinoshita,et al.  The role of systemic and topical fatty acids for dry eye treatment , 2017, Progress in Retinal and Eye Research.

[8]  A. Afeltra,et al.  Polyunsaturated fatty acids: any role in rheumatoid arthritis? , 2017, Lipids in Health and Disease.

[9]  D. Karamichos,et al.  The role of lipids in corneal diseases and dystrophies: a systematic review , 2017, Clinical and Translational Medicine.

[10]  D. Chang,et al.  Endophthalmitis Reduction with Intracameral Moxifloxacin Prophylaxis: Analysis of 600 000 Surgeries. , 2017, Ophthalmology.

[11]  J. Talamo,et al.  Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza™): results of a qualitative survey , 2017, Patient preference and adherence.

[12]  Emily W. Gower,et al.  Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. , 2017, The Cochrane database of systematic reviews.

[13]  A. Grzybowski,et al.  Dropless Cataract Surgery: An Overview. , 2017, Current pharmaceutical design.

[14]  Algis J Vingrys,et al.  A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease. , 2017, Ophthalmology.

[15]  A. Grzybowski,et al.  Pseudophakic cystoid macular edema: update 2016 , 2016, Clinical interventions in aging.

[16]  M. Kahook,et al.  Cataract surgery and nonsteroidal antiinflammatory drugs , 2016, Journal of cataract and refractive surgery.

[17]  S. Lane,et al.  Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes , 2016, Cornea.

[18]  H. Flynn,et al.  Antibiotic prophylaxis: different practice patterns within and outside the United States , 2016, Clinical ophthalmology.

[19]  L. Tong,et al.  Lipid-Based Therapy for Ocular Surface Inflammation and Disease. , 2015, Trends in molecular medicine.

[20]  S. Masket,et al.  Sustained‐release dexamethasone for the treatment of ocular inflammation and pain after cataract surgery , 2015, Journal of cataract and refractive surgery.

[21]  Daniel Monleón,et al.  A metabolomic approach to dry eye disorders. The role of oral supplements with antioxidants and omega 3 fatty acids , 2015, Molecular vision.

[22]  J. Ji,et al.  Omega-3 Essential Fatty Acids Therapy for Dry Eye Syndrome: A Meta-Analysis of Randomized Controlled Studies , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[23]  Soo-Hyun Park,et al.  Effects of Eye Drops Containing a Mixture of Omega-3 Essential Fatty Acids and Hyaluronic Acid on the Ocular Surface in Desiccating Stress-induced Murine Dry Eye , 2014, Current eye research.

[24]  Q. Nguyen,et al.  Emerging Therapies for Noninfectious Uveitis: What May Be Coming to the Clinics , 2014, Journal of ophthalmology.

[25]  R. Klein,et al.  Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. , 2014, American journal of ophthalmology.

[26]  Hyo Myung Kim,et al.  Current Practice Pattern for Dry Eye Patients in South Korea: A Multicenter Study , 2014, Korean journal of ophthalmology : KJO.

[27]  G. Laurie,et al.  Lacritin and the tear proteome as natural replacement therapy for dry eye. , 2013, Experimental eye research.

[28]  A. Moser,et al.  Red blood cell fatty acid analysis for determining compliance with omega3 supplements in dry eye disease trials. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[29]  M. Pinazo-Durán,et al.  Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders , 2013, Clinical interventions in aging.

[30]  M. Leitritz,et al.  Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial , 2012, Clinical ophthalmology.

[31]  E. Donnenfeld.  Current Use of Non-steroidal Anti-inflammatory Drugs in the Treatment of Ocular Inflammation Related to Cataract Surgery , 2012 .

[32]  C. Asche,et al.  The Economic Burden of Dry Eye Disease in the United States: A Decision Tree Analysis , 2011, Cornea.

[33]  K. Tsubota,et al.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. , 2011, Investigative ophthalmology & visual science.

[34]  T. Comstock,et al.  Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery , 2011, Clinical ophthalmology.

[35]  K. Hammersmith,et al.  Topical Omega-3 and Omega-6 Fatty Acids for Treatment of Dry Eye , 2009 .

[36]  J. Buring,et al.  Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. , 2005, The American journal of clinical nutrition.

[37]  De-Quan Li,et al.  Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. , 2004, Investigative ophthalmology & visual science.